Alector (ALEC) Cash from Investing Activities (2018 - 2026)
Alector (ALEC) reported Cash from Investing Activities of $60.9 million for Q1 2026, down 7.28% year-over-year from $65.7 million in Q1 2025, and up 138.1% quarter-over-quarter from $25.6 million in Q4 2025.
Alector (ALEC) Cash from Investing Activities (2018 - 2026) Analysis & Trends
Alector (ALEC) has 9 years of Cash from Investing Activities data on file, last reported at $60.9 million in Q1 2026.
- Cash from Investing Activities for Q1 2026 came in at $60.9 million, down 7.28% year-over-year; the trailing twelve-month figure through Mar 2026 was $191.8 million (up 3.89% YoY), and the FY2025 annual result was $196.6 million, up 83.51% from the prior year.
- Cash from Investing Activities improved to $60.9 million in Q1 2026 per ALEC's latest filing, from $25.6 million in the prior quarter.
- Over five years, Cash from Investing Activities peaked at $88.7 million in Q1 2023 and troughed at -$225.8 million in Q2 2022.
- A 5-year average of $18.1 million and a median of $37.1 million in 2024 frame the typical range for Cash from Investing Activities.
- The sharpest annual moves came in 2022 and 2023: Cash from Investing Activities plunged 499.04% in 2022, then jumped 832.7% in 2023.
- A 5-year view of Cash from Investing Activities shows it stood at $18.4 million in 2022, then decreased by 1.69% to $18.1 million in 2023, then jumped by 129.11% to $41.4 million in 2024, then slumped by 38.17% to $25.6 million in 2025, then jumped by 138.1% to $60.9 million in 2026.
- Business Quant data shows ALEC's Cash from Investing Activities at $60.9 million in Q1 2026, $25.6 million in Q4 2025, and $49.5 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.89 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 638.50 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | -431.90 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 579,519.10 |
| 10 | Alector | 193.53 Mn | -12.98 Mn | - | 60.95 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 60.95 Mn |
| Mar 31, 2026 | 60.95 Mn |
| Dec 31, 2025 | 25.60 Mn |
| Dec 31, 2025 | 25.60 Mn |
| Sep 30, 2025 | 49.54 Mn |
| Sep 30, 2025 | 49.54 Mn |
| Jun 30, 2025 | 55.72 Mn |
| Jun 30, 2025 | 55.72 Mn |
| Mar 31, 2025 | 65.74 Mn |
| Mar 31, 2025 | 65.74 Mn |
| Dec 31, 2024 | 41.40 Mn |
| Dec 31, 2024 | 41.40 Mn |
| Sep 30, 2024 | 40.35 Mn |
| Sep 30, 2024 | 40.35 Mn |
| Jun 30, 2024 | 37.15 Mn |
| Jun 30, 2024 | 37.15 Mn |
| Mar 31, 2024 | -11.77 Mn |
| Mar 31, 2024 | -11.77 Mn |
| Dec 31, 2023 | 18.07 Mn |
| Dec 31, 2023 | 18.07 Mn |